Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

NCT02766608 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2389

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disorder

Interventions

DRUG: BFF MDI 320/9.6 μg
DRUG: BFF MDI 160/9.6 μg
DRUG: FF MDI 9.6 μg
DRUG: BD MDI 320 μg
DRUG: Symbicort® TBH 400/12 μg BID

Sponsor

Pearl Therapeutics, Inc.